Yanni Souroutzidis

Stock Analyst at Cantor Fitzgerald

(1.82)
# 5,142
Out of 5,182 analysts
1
Total ratings
50%
Success rate
9.47%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Yanni Souroutzidis

Karyopharm Therapeutics
Feb 5, 2026
Initiates: Overweight
Price Target: n/a
Current: $8.60
Upside: -